Reliably manufacturing consistent LNPs was another challenge, and producing the raw materials needed to make the particles is a limiting factor in the production of COVID-19 vaccines today.

Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

The global lipid nanoparticles market is on the cusp of remarkable expansion, projected to grow at a CAGR of 14% through 2035, according to a recent industry analysis. Estimated to generate USD 1,144.

Cambridge, Massachusetts-based Alnylam sued Pfizer and BioNTech in 2022, alleging their COVID-19 vaccines infringed patents ...

Federal health officials will no longer routinely approve annual COVID-19 shots for younger adults and children who are ...

Scientists have developed a method for analysing the structure of lipid nanoparticles that could be used to improve vaccine ...

A new PEARLS article in PLoS Pathogens reviews the rapid evolution and pandemic potential of emerging influenza A viruses, ...

The mRNA platform market holds significant opportunities, driven by advancements in LNP delivery systems, codon optimization, and synthetic biology tools like CRISPR-Cas9. These innovations support ...

Following the COVID-19 pandemic, mRNA-based vaccines have been shown to provide rapid and precise immune responses, however, this technology has much wider applications. Many leading pharma and ...